Regenerative Medicine Industry News - Stem Cells, Cord Blood, Exosomes, CAR-T, and Beyond [March 2021]

Below we feature regenerative medicine industry news for March 2021, including coverage of stem cells, cord blood, exosomes, CAR-T, and beyond. Please enjoy and share.

The Best Cord Blood Bank of 2021: Which One Should You Choose?

After choosing a name for your newborn, the next decision you’ll need to make is whether or not you want to save their cord blood. It’s a choice you will need to make swiftly, as the window to successfully store your child’s cord blood and cord tissue is a relatively small one. While there is a lot of information available for expecting parents, sifting through all the options to find the best cord blood bank can be overwhelming, especially if you’re not familiar with all the terms and technology.

U.S. FDA Grants Approval of Fourth CAR-T Cell Therapy (Breyanzi) to Juno Therapeutics

The U.S. FDA has granted approval of Breyanzi (lisocabtagene maraleucel) to Juno Therapeutics, a Bristol-Myers Squibb Company. Breyanzi is a CAR-T cell therapy for the treatment of adults with relapsed or refractory large-B-cell lymphoma who have not responded to, or who have relapsed after, at least two types of systemic treatment. It is the FDA’s fourth approval of a CAR-T cell therapy, which now include Kymriah, Yescarta, Tecartus, and Breyanzi. It is also the first therapy with RMAT designation to be licensed by the U.S. FDA.

Ciloa’s project among the 11 winners of the “Sanofi iTech Awards”

Ciloa, a pioneer company specialized in the in vivo customization of exosomes, announced the selection of its project as part of the “Sanofi iTech Awards” program. It is the first time that this program has selected innovative projects led by biotechnology companies. Consequently, Ciloa will receive funding and scientific support from Sanofi throughout 2021.

Cord Blood Industry Consolidation Escalates in 2021

The cord blood industry experienced strong growth from the early 1990’s through the late 2000’s, during which time more than 450 cord blood banking companies emerged worldwide. Approximately half of those companies owned their own labs, while the others were marketing entities or sub-contractors of storage space. Starting about ten years ago, the market suddenly changed course. It entered a period of aggressive consolidation, cutting the global number of cord blood banks by approximately half. This articles explores examples of cord blood industry consolidation, as well as their impact on the industry at large.

New Lab at UF’s Sid Martin Biotech to Pave Way for Post-COVID Therapy, Regenerative Medicine Research9

The inflammation COVID-19 patients suffer during and post-COVID-19 infection (AKA “Post-COVID Syndrome”) will be one of many focuses of a new Research & Development laboratory recently launched at the University of Florida Sid Martin Innovate Biotechnology Institute, the world-recognized leader in biotechnology incubation. Neobiosis, which produces regenerative tissues, cells and extracellular vesicles for research and clinical trials to help the body heal itself—without surgery—will operate the laboratory at the biotech center, located in Alachua, Fla.

Nucleus Biologics Launches Artificial Intelligence Research (NB-AIR): The World’s First AI Platform for Media Configuration That Gives Control Back To The Scientists

Nucleus Biologics?, The Cell Performance Company?, announced the availability of NB-AIR?, the world’s first Artificial Intelligence Research platform for optimizing cell culture formulations for cell and gene therapies. Leveraging cutting-edge AI algorithms, the system empowers scientists to create optimized formulas based on meta-analysis of peer-reviewed articles. AI guided formulations will allow scientists to improve the performance of their cell therapy and shorten the time to get these lifesaving therapies into patients faster.

Organicell Announces FDA Approval Of IND Application for the Use of Zofin? In The Treatment Of Chronic Obstructive Pulmonary Disease (COPD)

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin?, in the treatment of patients diagnosed with chronic obstructive pulmonary disease (COPD).

Notch Therapeutics Closes $85M Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies

Notch Therapeutics, Inc., a company developing renewable, iPSC-derived cell therapies for cancer, closed an oversubscribed U.S. $85M Series A financing. The financing was led by a healthcare-focused investment fund, with participation by existing investors Allogene Therapeutics, Inc. (NASDAQ: ALLO), Lumira Ventures, and CCRM Enterprises Holdings Ltd., an affiliate of Centre for Commercialization of Regenerative Medicine; along with new investors EcoR1 Capital, Casdin Capital, Samsara BioCapital, and Amplitude Ventures.

Century Therapeutics Significantly Expands Capabilities with New Operational, Laboratory and Manufacturing Facilities in Pennsylvania and New Jersey

Century Therapeutics, a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced a significant expansion of its operational and laboratory space in Philadelphia, as well as progress on its manufacturing facility in Branchburg, NJ, paving the way for a strong technical foundation as the company scales up its in-house research and development capabilities.

Market for cord blood and perinatal tissue in 2021

Over the past 30 years, cord blood and cord tissue have gained popularity and commercial traction due to the valuable stem cells they contain. Today, novel pricing strategies, product cross-sells and upsells, and ingenious online and offline marketing strategies are being implemented by the industry’s market leaders. Meanwhile, new technologies to support ex vivo cord blood expansion are advancing at brisk speed.

CAR-T Financing Frenzy: $100 Billion in Market Cap by CAR-T Companies

CAR-T funding is on the rise. At first the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus and Breyanzi reached the marketplace and created a CAR-T funding craze. In total, financing rounds by CAR-T companies are approaching a total value of $4 billion, while CAR-T industry partnerships contribute $2 billion. There has also been nearly $100 billion of market capitalization from CAR-T companies within recent years. Ranging from small start-ups to billion dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer. This article provides a comprehensive list of CAR-T therapy companies worldwide. Read on to learn more about innovative CAR-T cell therapy companies and the technologies they are using to fight cancer.

MSCs, the Latest Weapon Being Leveraged in Regenerative Medicine (RM)

This articles explores the rise of MSCs within the regenerative medicine. MSCs are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. 

Cytovia Therapeutics and Cellectis Partner to Develop TALEN? Gene-Edited iPSC-Derived Natural Killer Cells

Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from iPSCs, and Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), have entered into a strategic research and development collaboration to develop TALEN? gene-edited iPSC NK and CAR-NK cells.

Award winning celebrity doctor secures a year’s worth of Stem Cell expansions exclusively for his patients

LifePlus Stem Cells secures an exciting new partnership with award winning celebrity doctor Aamer Khan. The London based doctor has had a special interest in Regenerative Medicine for more than 10 years and is excited to offer his patients the very latest in stem cell therapies. His patients will be able to choose from umbilical cord tissue-derived mesenchymal stromal cells (allogeneic) or their own, purified and expanded, adipose tissue-derived stem cells (autologous) for various medical treatments.

What Is the Future of the Stem Cell Market in 2021?

Stem cell therapy continues to rally worldwide recognition as governments fund research and expand access. This once-controversial therapy is fast becoming one of medicine’s most exciting technologies. From FDA-approved therapies to in-house, physician-initiated autologous techniques, stem cell technology continues to evolve. 2021 promises to be an exciting year for the stem cell market.

Stem Cell Treatments For Macular Degeneration

Macular degeneration is a crushing condition, leading to loss of visual acuity, and in some cases, eventual blindness. Even those who don’t experience total eyesight loss suffer a frustrating degradation of central vision, which makes driving, using a computer or other devices, recognizing faces, reading, and many other activities nearly impossible to do. However, recent advancements in stem cell treatments for macular degeneration are providing a beacon of hope to many.

Induced Pluripotent Stem Cell (iPSC) Applications in 2021

Since the discovery of iPSCs in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. Today, there are at least eight distinct iPSC applications ranging from cell therapy to toxicology, drug development, and beyond.

Stem Cell Infusion: What to Expect

In recent years, stem cell infusion has become a breakthrough technology. There have been multiple medical leaders citing regenerative medicine as the way of the future. Stem cells obviate our need to patch up the body or create stopgap measures for systems that don’t work. They instead promise to replace organs and tissues that no longer function, essentially rebuilding the body from the inside out.

Regenerative Medicine’s Competitive Advantage

Regenerative medicine is the process of replacing or repairing human genes, cells, tissues or organs in order to restore healthy function. It is the processing of working with the human body to assist it to heal itself. In that sense, it is about working “with” biology, instead of against or separate from it. The commercialization of regenerative therapies is also early stage, which makes this market relatively uncontested. It is a classic “blue ocean” for those familiar with the concept.

Global Cord Blood Banking Industry Report 2021

The cord blood industry has been witnessing record levels of M&A activity, with large investment groups vying for acquisition opportunities and industry consoliation happening in all major markets worldwide. Simultaneously, the release of cord blood units (CBUs) for preclinical and clinical trial investigation has been surging. When paired with clinical trials evaluating the use of cord tissue-derived cells for RM applications, the numbers are staggering. Immediately access cord blood and tissue market trends, competitive insights, storage metrics, marketing and pricing strategies, market size figures, market segmention, 5-year forecasts, and so much more.

To access other market insights about stem cells, CAR-T, exosomes and more, explore the BioInformant Shop.